MIGRANAL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Migranal, and what generic alternatives are available?
Migranal is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in MIGRANAL is dihydroergotamine mesylate. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Migranal
A generic version of MIGRANAL was approved as dihydroergotamine mesylate by PADAGIS US on April 28th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MIGRANAL?
- What are the global sales for MIGRANAL?
- What is Average Wholesale Price for MIGRANAL?
Summary for MIGRANAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Clinical Trials: | 3 |
| Patent Applications: | 1,250 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for MIGRANAL |
| What excipients (inactive ingredients) are in MIGRANAL? | MIGRANAL excipients list |
| DailyMed Link: | MIGRANAL at DailyMed |
Recent Clinical Trials for MIGRANAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Impel NeuroPharma Inc. | Phase 1 |
| Stanford University | Phase 2 |
| Thomas Jefferson University | Phase 4 |
Pharmacology for MIGRANAL
| Drug Class | Ergotamine Derivative |
US Patents and Regulatory Information for MIGRANAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | MIGRANAL | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 020148-001 | Dec 8, 1997 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MIGRANAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | MIGRANAL | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 020148-001 | Dec 8, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | MIGRANAL | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 020148-001 | Dec 8, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | MIGRANAL | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 020148-001 | Dec 8, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MIGRANAL
See the table below for patents covering MIGRANAL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | H0253406 | ⤷ Sign Up | |
| Austria | A825477 | ⤷ Sign Up | |
| Netherlands | 187892 | ⤷ Sign Up | |
| Sweden | 454402 | NASALT ADMINISTRERBAR FARMACEUTISK KOMPOSITION INNEHALLANDE EN ERGOTPEPTIDALKALOID SAMT ETT XANTIN | ⤷ Sign Up |
| Hungary | 191512 | PROCESS FOR PRODUCTION OF DOSED THROUGH THE NOSE MEDICAL PREPARATIVES CONTAINING ERGOT-ALCALOIDS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
